{"disease":{"id":"diarrhea-secondary-to-inflammatory-bowel-disease","name":"Diarrhea Secondary to Inflammatory Bowel Disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"loperamide","indication_name":"Diarrhea Secondary to Inflammatory Bowel Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imodium","generic_name":"loperamide","company_name":"Johnson & Johnson (McNeil Consumer Healthcare)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Cocaine esterase, D(4) dopamine receptor","drug_class":"Antidiarrheal (peripheral opioid agonist)","quality_score":null,"revenue":null,"mechanism":"Peripheral mu-opioid receptor agonist that slows intestinal motility and increases fluid absorption without crossing the blood-brain barrier."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}